Home › Research › Biomarkers
Effects of obesity on plasma biomarker and amyloid PET trajectories in Alzheimer's disease
Soheil Mohammadi, Farzaneh Rahmani, Mahsa Dolatshahi, Suzanne E Schindler, Cyrus A Raji, ADNI Collaborators. Alzheimer's & dementia (Amsterdam, Netherlands), 2025-07-03
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
Higher body mass index at baseline was correlated with lower levels of plasma phosphorylated tau (p-tau)217, p-tau217 ratio, neurofilament light chain (NfL), glial fibrillary acidic protein, and CLs. However, baseline obesity predicted higher rate of increase in p-tau217, p-tau217 ratio, Roche NfL, and amyloid PET burden over time. This study provides insights for longitudinal changes in AD pathologies, as measured by BBM levels and CLs, in association with obesity. HIGHLIGHTS: Higher body mass index was related to lower baseline plasma tau phosphorylated at threonine 217 (p-tau217), p-tau217, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) and amyloid positron emission tomography (PET) burden.Obesity predicts a faster increase in p-tau217, p-tau217 ratio, and NfL.Obesity predicts a faster increase in amyloid PET burden.Changes in GFAP over time are not linked with obesity.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Mohammadi, S., Rahmani, F., Dolatshahi, M., Schindler, S. E., Raji, C. A., & ADNI Collaborators. (2025). Effects of obesity on plasma biomarker and amyloid PET trajectories in Alzheimer's disease. Alzheimer's & dementia (Amsterdam, Netherlands). https://doi.org/10.1002/dad2.70143
Vancouver
Mohammadi S, Rahmani F, Dolatshahi M, Schindler SE, Raji CA, ADNI Collaborators. Effects of obesity on plasma biomarker and amyloid PET trajectories in Alzheimer's disease. Alzheimer's & dementia (Amsterdam, Netherlands). 2025. doi:10.1002/dad2.70143. PMID: 40620424.
BibTeX
@article{mohammadi2025-40620424,
author = {Mohammadi, Soheil and Rahmani, Farzaneh and Dolatshahi, Mahsa and Schindler, Suzanne E and Raji, Cyrus A and {ADNI Collaborators}},
title = {{Effects of obesity on plasma biomarker and amyloid PET trajectories in Alzheimer's disease}},
journal = {Alzheimer's \& dementia (Amsterdam, Netherlands)},
year = {2025},
doi = {10.1002/dad2.70143},
pmid = {40620424},
url = {https://doi.org/10.1002/dad2.70143}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Higher body mass index at baseline was correlated with lower levels of plasma phosphorylated tau (p-tau)217, p-tau217 ratio, neurofilament light chain (NfL), glial fibrillary acidic protein, and CLs.
- However, baseline obesity predicted higher rate of increase in p-tau217, p-tau217 ratio, Roche NfL, and amyloid PET burden over time.
- This study provides insights for longitudinal changes in AD pathologies, as measured by BBM levels and CLs, in association with obesity.
- HIGHLIGHTS: Higher body mass index was related to lower baseline plasma tau phosphorylated at threonine 217 (p-tau217), p-tau217, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) and amyloid positron emission tomography (PET) burden.Obesity predicts a faster increase in p-tau217, p-tau217 ratio, and NfL.Obesity predicts a faster increase in amyloid PET burden.Changes in GFAP over time are not linked with obesity.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcross-sectional
- Evidence strengthModerate
How this study scored 57/100
Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 32 of the 56 points we could judge it on, which is 57 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia (Amsterdam, Netherlands)) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40620424) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 32 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 32 of the 56 points we could judge it on is 57 out of 100. |
| Total | 57 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “18f”
318 studies in the library carry the topic tag “18f”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 318 tagged studies.